ImmunityBio, Inc. Common Stock
Here’s whether ImmunityBio, Inc. Common Stock (IBRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: trading above the 200-day MA (long-term uptrend intact); strong 1-year return of +135.9%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.24% over 10 days); RSI 26 — oversold. Currently 42.9% off its 52-week high. Score: +0/7.
IBRX is holding above its long-term 200-day MA ($5.80) but has slipped below the 50-day MA ($7.77), pointing to short-term weakness in an otherwise intact trend. An RSI of 26.3 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +135.9% compares to +16.5% for SPY (beat the market by 119.4%). The current 42.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.